Skip Navigation


NDT Advance Access originally published online on July 7, 2008
Nephrology Dialysis Transplantation 2008 23(9):2746-2749; doi:10.1093/ndt/gfn349
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/9/2746    most recent
gfn349v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Le, M. T.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le, M. T.
Right arrow Articles by Johnson, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


SLC2A9—a fructose transporter identified as a novel uric acid transporter*

MyPhuong T. Le1, Mohamed Shafiu2, Wei Mu2 and Richard J. Johnson3

1 Department of Pharmacy Practice, Center for Pharmacogenomics 2 Department of Nephrology, College of Medicine 3 Department of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, FL, USA

Correspondence and offprint requests to: MyPhuong T. Le. College of Pharmacy, University of Florida, P.O. Box 100486, Gainesville, FL 32610, USA Tel: 352-273-6007; Fax: 352 273 6121; E-mail: bachlee{at}ufl.edu

Keywords: fructose transporter; GLUT9; SLC2A9; uric acid transporter



   Key findings
Top
 Key findings
Brief review
 Discussion
 Take home message
 References
 
SLC2A9 was recently cloned and identified as a member of the SLC2A gene family of hexose facilitative transporters, where its main physiological role was assumed to be in the transport of glucose and fructose. However, new findings have unearthed a novel role for SLC2A9 (also known as GLUT9) as a modulator of uric acid levels. Specifically, after conducting genome-wide scans, Doring et al. and Vitart et al. have identified several noncoding genetic variants of SLC2A9 that were strongly associated with a decrease in serum uric acid concentrations and an increase in fractional excretion of uric acid. Accordingly, the variants were also associated with a decreased risk of gout, suggesting a protective role for the minor alleles. Interestingly, in both of the studies, gender-specific effects were more pronounced in women than in men. Doring et al. estimated the additive effect to be –0.45 mg/ dl per copy of the minor allele in women and –0.25 mg/ dl in men. Overall, genetic variants of SLC2A9 are potentially responsible for 1.2–6.0% of the variance in serum uric acid concentrations. Of importance is the functional determination that SLC2A9 is a strong urate transporter, implicating it as a key player in the renal excretion of uric acid that could greatly impact clinical practices.



   Brief review
Top
 Key findings
 Brief review
Discussion
 Take home message
 References
 
Unlike most mammals, humans cannot regulate uric acid levels very effectively, largely because of the mutational loss of uricase (urate oxidase) that degrades uric acid to allantoin. A major consequence of the lack of this hepatic enzyme is a relatively unique susceptibility of humans to develop hyperuricemia in response to diet, such as from purine-rich meats, seafood and beer. In addition, fructose, which is present in table sugar or sucrose, the sweetener high fructose corn syrup and fruits, can raise uric acid levels due to the unique ability of this sugar to cause intracellular ATP depletion and adenine nucleotide turnover.

While diet is likely a key factor in modulating uric acid levels in the population, genetic mechanisms are also known to be important regulators of uric acid concentrations which is considered to be strongly heritable, ranging from 25 to 73% [1,2]. Some rare genetic causes of hyperuricemia include those associated with the de novo purine synthesis pathway, such as complete or partial deficiency in hypoxanthine–guanine phosphoribosyltransferase and increased phosphoribosylpyrophosphate synthetase (PRPP). More recently, the disease, familial juvenile hyperuricemic nephropathy (FJHN), was found to be due to mutation in uromodulin (Tamm Horsfall protein). Although elevated uric acid can be caused by the increased breakdown of endogenous and exogenous purines, impairments of the renal excretion of uric acid is the main cause of ~90% of all hyperuricemia incidents; thus, it is more clinically significant [3,4]. Renal transport of uric acid is governed by a complex system of transporters in the proximal tubule (Figure 1) [4,5]. Several genetic polymorphisms in the apical transporter, URAT1, have already been linked with hyperuricemia [6,7]. In addition, mutational loss of URAT1 can cause the rare syndrome of hypouricemia with exercise-induced acute renal failure [8].


Figure 1
View larger version (84K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Urate transport in the proximal tubule. Several transporters have recently been identified as potential molecular components in the renal transport of urate [4,5]. URAT1, a urate-anion exchanger, and OAT4, an organic anion-dicarboxylate exchanger, are mediators of urate reabsorption. URAT1 is considered to be a key player in uric acid homeostasis and has been estimated to be responsible for 50% of urate reabsorption. Its activity, however, is driven by sodium-anion transporters, potentially by SLC5A8 and SLC5A12, which provide the main source of anions needed for URAT1 function. For urate secretion into the lumen, a urate transporter/channel (UAT), a voltage-driven organic anion transporter (OATv1 or NPT1) and an ATP-binding cassette transporter (MRP4) are potential efflux candidates. Although very little is known about the basolateral transport of urate, two anion-dicarboxylate transporters, OAT1 and OAT3, have been shown to have the ability to transport urate, but the direction of the urate transport still needs to be characterized. Furthermore, their activity may be coupled with SLC13A3 that drives the intake of Na+ and dicarboxylates. In addition to all these transporters, SLC2A9 has been discovered to be a candidate protein in the excretion of urate and may play a dominant role in urate reabsorption [12]. The short isoform, SLC2A9v2, localizes exclusively to the apical membrane and has been shown to transport urate. The role of the long isoform, SLC2A9v1, on the uric acid transport remains to be elucidated.

 
Recently, genome-wide studies have been conducted to identify new genes involved in uric acid homeostasis. Several loci associated with hyperuricemia have been identified, including in chromosome 4q25 observed in Taiwanese aborigines [4], in chromosomes 2, 8 and 15 in the Framingham Heart Study [2] and in chromosome 6q22–23 in Mexican Americans [1]. However, one of the most striking associations was localized to SLC2A9 on chromosome 4p15.3–16. After conducting genome-wide scans by utilizing chips consisting of 300K–500K single nucleotide polymorphisms (SNPs), genetic variants of SLC2A9 were strongly associated with reduced levels of serum uric acid in Caucasian cohorts from Italy [9,10], the UK [11], Croatia [12], the United States [10], Germany and Austria [13]. The strongest associations were mapped to noncoding SNPs located near the 5' of the gene and within introns 3–7, but further studies are needed to elucidate their impact on the protein's function. Interestingly, SLC2A9 polymorphisms (rs6855911, rs7442295, rs6449213, rs12510549, rs737267 and rs1014290) were shown to have gender-specific effects on uric acid concentrations, resulting in a greater reduction in women (–0.352 to –0.880 mg/dl) than in men (–0.128 to –0.428 mg/dl) (Table 1). Consequently, genetic variants of SLC2A9 are potentially responsible for 5.3–6.0% of the variance in serum uric acid concentrations in women and 1.2–1.7% in men.


View this table:
[in this window]
[in a new window]

  		Table 1 SLC2A9 SNPs showing gender-specific effects on serum uric acid concentrations

 
How do alterations in SLC2A9 alter serum uric acid levels? Recent studies suggest that one mechanism may be by modulating renal excretion of uric acid. There are two common variants of SLC2A9 (GLUT9): a long isoform (SL2A9v1) and a short isoform (SLC2A9v2) [14]. From in vitro studies, it was shown that the long isoform trafficked predominantly to the basolateral membrane of proximal tubule epithelial cells while the short isoform was exclusively localized to the apical membrane. Utilizing Xenopus laevis oocytes, SLC2A9v2 was shown to have a high capacity for the urate transport [12]. Polymorphisms of SLC2A9 were also shown to be associated with the increased fractional excretion of uric acid, suggesting that these polymorphisms may effectively modulate uric acid excretion.



   Discussion
Top
 Key findings
 Brief review
 Discussion
Take home message
 References
 
There is a growing interest in understanding the genetic determinants of urate homeostasis due to the concern that elevated serum uric acid concentrations may be a risk factor for several common disorders, including gout, hypertension [15], metabolic syndrome [16,17], cardiovascular disease [18], type 2 diabetes mellitus [19], diabetic nephropathy [20] and kidney disease [21,22]. The discovery of SLC2A9, along with other proteins involved in the urate transport, may greatly impact our understanding of uric acid homeostasis. Clinically, new insights in this field can enhance the utilization of current medications and can generate novel genetic therapeutic targets for the control of uric acid concentrations. For instance, with the discovery of URAT1, the assumed action of pyrazine carboxylic acid (PZA) as an inhibitor of urate secretion has been debunked. Instead, PZA has been shown increase urate reabsorption by stimulating URAT1 activity, thus invalidating the four-component model of the renal urate transport [4].

Since fructose itself results in uric acid generation, the observation that SLC2A9, a fructose transporter, can also function as a urate transporter raises the interesting possibility that this transporter may ‘fine tune’ the movement of uric acid in and out of the cell in response to fructose. For example, a polymorphism of SLCA29 could lead to a relatively higher concentration of uric acid within the cell in response to fructose. The importance of this potential function could be significant given recent studies suggesting that fructose-induced hyperuricemia may have a critical role in mediating the metabolic syndrome [23] and by studies suggesting that intracellular uric acid levels may largely mediate many of the pro-inflammatory effects of uric acid in various cell types [24]. Besides being expressed in a variety of other sites, such as the liver, placenta, brain, lung and leukocytes, SLC2A9 is also expressed in chrondrocytes [12,14,25]. Can SLC2A9 be responsible for the buildup of urate in gouty arthritis?

Combined with its strong activity as a urate transporter and the strong associations between genetic variants of SLC2A9 and serum uric acid concentrations, SLC2A9 is an important modulator of uric acid levels. Interestingly, it was the minor alleles of the genetic variants of SLC2A9 that was associated with reduced levels of serum uric acid levels. Assuming that the mutations impair the function of the protein, SLC2A9 is then implicated as an essential player in inducing hyperuricemia in humans. Thus, individuals with the mutations are protected and less likely to develop gout and potentially other disorders. Furthermore, SLC2A9 may be important to the underlining differences in uric acid concentrations reported between women and men.



   Take home message
Top
 Key findings
 Brief review
 Discussion
 Take home message
References
 
Serum uric acid levels and renal uric acid excretion have been found to be modulated by genetic polymorphisms in SLC2A9, a fructose transporter, which can influence the risk for gout by affecting renal urate reabsorption.



   Acknowledgments
 
This work was supported by NIH training grant NIDDK T32-7518 (to M. Le), NIH RO-1 HL-68607 and generous funds from Gatorade.

Conflict of interest statement. None declared.



   Notes
 
* References of Articles: Back

1 Doring A, Gieger C, Mehta D et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40: 430–436.

2 Vitart V, Rudan I, Hayward C et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437–442.



   References
Top
 Key findings
 Brief review
 Discussion
 Take home message
 References
 

  1. Nath SD, Voruganti VS, Arar NH, et al. Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol (2007) 18:3156–3163.[Abstract/Free Full Text]
  2. Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart study. Metabolism (2005) 54:1435–1441.[CrossRef][Web of Science][Medline]
  3. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther (2006) 8(Suppl_1):S4.
  4. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am (2006) 32:313–331. vi.[CrossRef][Web of Science][Medline]
  5. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol (2007) 19:151–157.[Web of Science][Medline]
  6. Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum (2006) 54:292–300.[CrossRef][Web of Science][Medline]
  7. Vazquez-Mellado J, Jimenez-Vaca AL, Cuevas-Covarrubias S, et al. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) (2007) 46:215–219.[CrossRef][Medline]
  8. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol (2004) 15:164–173.[Abstract/Free Full Text]
  9. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in sardinia and chianti cohorts. PLoS Genet (2007) 3:e194.[CrossRef][Medline]
  10. Brandstätter A, Kiechl S, Kollerits B, et al. The gender-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care (2008) May 16 [Epub ahead of print].
  11. Wallace C, Newhouse SJ, Braund P, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet (2008) 82:139–149.[CrossRef][Web of Science][Medline]
  12. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet (2008) 40:437–442.[CrossRef][Web of Science][Medline]
  13. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet (2008) 40:430–436.[CrossRef][Web of Science][Medline]
  14. Augustin R, Carayannopoulos MO, Dowd LO, et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem (2004) 279:16229–16236.[Abstract/Free Full Text]
  15. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol (2005) 25:3–8.[Web of Science][Medline]
  16. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health (2004) 4:9.[CrossRef][Medline]
  17. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care (2002) 25:1790–1794.[Abstract/Free Full Text]
  18. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke (2006) 37:1503–1507.[Abstract/Free Full Text]
  19. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care (2008) 31:361–362.[Abstract/Free Full Text]
  20. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol (2008) 3:706–713.[Abstract/Free Full Text]
  21. Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol (2008).
  22. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis (2007) 50:239–247.[CrossRef][Web of Science][Medline]
  23. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2006) 290:F625–F631.[Abstract/Free Full Text]
  24. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol (2005) 16:3553–3562.[Abstract/Free Full Text]
  25. Phay JE, Hussain HB, Moley JF. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics (2000) 66:217–220.[CrossRef][Web of Science][Medline]
Received for publication: 16. 5.08
Accepted in revised form: 28. 5.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
Q.-H. Hu, C. Wang, J.-M. Li, D.-M. Zhang, and L.-D. Kong
Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement
Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1080 - F1091.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Doherty
New insights into the epidemiology of gout
Rheumatology, May 1, 2009; 48(suppl_2): ii2 - ii8.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Dalbeth and T. Merriman
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout
Rheumatology, March 1, 2009; 48(3): 222 - 226.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. S. Voruganti, S. D. Nath, S. A. Cole, F. Thameem, J. B. Jowett, R. Bauer, J. W. MacCluer, J. Blangero, A. G. Comuzzie, H. E. Abboud, et al.
Genetics of Variation in Serum Uric Acid and Cardiovascular Risk Factors in Mexican Americans
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. M. Bataille, J. Goldmeyer, and J. L. Renfro
Avian renal proximal tubule epithelium urate secretion is mediated by Mrp4
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R2024 - R2033.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/9/2746    most recent
gfn349v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Le, M. T.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le, M. T.
Right arrow Articles by Johnson, R. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?